Royalty Pharma

Update in progress

RPRX (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Royalty Pharma plc is a buyer of biopharmaceutical royalties and a financier of innovation in the US biopharma sector. Its portfolio includes royalties on about 35 approved therapies and 20 development-stage product candidates across areas such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. Founded in 1996, it is based in New York, New York.

Company score

Sentiment: 0.44; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.03; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.25; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.10; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.10; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.27; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive